Left Ventricular Dysfunction Drugs in Development, 2022 Market Research Report: Pipeline Landscape, Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Left Ventricular Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
This pipeline guide provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Left Ventricular Dysfunction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and IND/CTA Filed stages are 3, 3, 2 and 1 respectively.
Left Ventricular Dysfunction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Left Ventricular Dysfunction (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Left Ventricular Dysfunction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular).
Key Topics Covered:
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Companies Involved in Therapeutics Development
- BioCardia Inc
- Help Therapeutics
- Innopharmax Inc
- Mesoblast Ltd
- Quantum Genomics SA
- Shanghai Life Science & Technology
- Takeda Pharmaceutical Co Ltd
- Valo Health LLC
- Viscofan BioEngineering
- AlloCSC-01 - Drug Profile
- CardiAMP - Drug Profile
- carvedilol CR - Drug Profile
- firibastat IR - Drug Profile
- NovoCardia - Drug Profile
- OPL-0301 - Drug Profile
- rexlemestrocel-L - Drug Profile
- Stem Cell Therapy for Left Ventricular Dysfunction - Drug Profile
- VBC-01 - Drug Profile
For more information about this report visit https://www.researchandmarkets.com/r/cd89ur.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900